-
Hansen Pharma's high-priced broad-spectrum antifungal drug was approved for Phase III clinical trials
Time of Update: 2022-01-11
In June 2021, ibrexafungerp (trade name: Brexafemme) was approved by the US FDA for the treatment of vulvovaginal candidiasis, becoming the first new antifungal approved in more than two decades, and the first and only vagina Non-azole therapy for yeast infections .
-
Shaoxing City, Zhejiang Province issued an emergency notice to suspend the sale of "category four" drugs in various pharmacies in the city
Time of Update: 2022-01-11
Coincidentally, Ningbo, Zhejiang Province initiated Level I emergency response on December 7, and various regions demanded that all pharmacies suspend the sale of "category four" drugs and implement the "removal of the shelf" treatment .
-
For obsessive-compulsive disorder!
Time of Update: 2022-01-11
According to the Chinese drug clinical trial registration and information disclosure platform, BioShin Limited (hereinafter referred to as "Biaoxin Company") has launched an international multi-center phase 3 clinical trial of troriluzole (BHV4157) for the treatment of obsessive-compulsive disorder in China .
-
The latest data of abutinib was announced at the 63rd Annual Meeting of the American Society of Hematology (ASH)
Time of Update: 2022-01-11
Professor Xu Wei, deputy director of the Department of Hematology, Jiangsu Provincial People’s Hospital, said: “This updated research result further confirms that compared with other BTK inhibitors, abutinib has a higher CR rate and faster in the treatment of R/R CLL patients.
-
WuXi Genuo announced at the 63rd Annual Meeting of the American Society of Hematology (ASH) the main clinical application of Benoda® (Rigiolense Injection) for the treatment of relapsed/refractory follicular lymphoma in Chinese adult patients Effect
Time of Update: 2022-01-11
Shanghai, December 13, 2021/PRNewswire/ - WuXi Juno (HKEx code: 2126), an independent and innovative biotechnology company focusing on the development, production and commercialization of cellular immunotherapy products, in At the 63rd Annual Meeting of the American Society of Hematology (ASH), the main clinical effects of Benoda® (Rigiolense Injection) for the treatment of relapsed/refractory follicular lymphoma in Chinese adult patients were announced .
-
Junshi PD-1 antibody combination is expected to expand indications for first-line treatment of patients with advanced lung cancer
Time of Update: 2022-01-11
(The original text has been deleted)Reference materials:[1] Coherus and Junshi Biosciences Announce Positive Interim Overall Survival Results of CHOICE-01, a Phase 3 Clinical Trial Evaluating Toripalimab in Combination with Chemotherapy as First-Line Treatment for Non-Small Cell Lung Cancer.
-
Protollin U.S. Phase 1 clinical study completed the first patient administration
Time of Update: 2022-01-11
On December 8, Tianjing Bio announced that the US Phase 1 clinical study of the new drug Protollin for the treatment of Alzheimer's disease has completed the first patient administration .
-
Disrupting the 20 billion antidepressant market Xinlitai's blockbuster drug stabilized?
Time of Update: 2022-01-11
Author: CloverRecently, Xinlitai issued a corporate announcement stating that the application for clinical trials of the innovative drug SAL0114 tablets independently developed by its company and intended to be used for severe depression has been accepted by the National Medical Products Administration .
-
Junshi Bio's PD-1 inhibitor first-line treatment of non-small cell lung cancer is accepted by CDE
Time of Update: 2022-01-11
Transfer from | Pharmaceutical Mission HillsOn December 10th, Junshi Biotech announced that the National Medical Products Administration (NMPA) of China has accepted its self-developed anti-PD-1 monoclonal antibody drug teriprizumab combined with standard first-line chemotherapy for untreated, driver genes A new indication for the marketing of negative advanced non-small cell lung cancer (NSCLC) is the sixth listing application submitted by Teriplizumab in China .
-
Pfizer/BioNTech modified the trial design to evaluate the effect of enhanced needles for children 6 months to 5 years old
Time of Update: 2022-01-11
If positive results from this trial are obtained, Pfizer and BioNTech expect to submit data to regulatory agencies in the first half of 2022 to seek approval for the emergency use authorization (EUA) of the new crown vaccine booster injection for children 6 months to 5 years old .
-
GSK/Vir neutralizing antibody Sotrovimab approved in the EU for early treatment of COVID-19
Time of Update: 2022-01-11
In May, the US FDA granted emergency use authorization (EUA) for the COVID-19 monoclonal antibody drug sotrovimab for mild to moderate adults and adults who tested positive for the virus and were at high risk of developing severe COVID-19 (including hospitalization and death).
-
Jingxin Pharmaceutical completes 205 million yuan acquisition of Shaxi Pharmaceutical
Time of Update: 2022-01-11
In order to strengthen the large varieties of traditional Chinese medicine and enhance the brand influence, another large pharmaceutical company has spent more than 200 million yuan on the acquisition0101205 million, Jingxin Pharmaceutical completed the acquisition205 million, Jingxin Pharmaceutical completed the acquisitionOn December 15, Zhejiang Jingxin Pharmaceutical issued an announcement on the acquisition of 100% equity of Guangdong Shaxi Pharmaceutical and related transactions .
-
Hongri Pharmaceutical: Rocuronium Bromide Injection Obtained Drug Registration Approval
Time of Update: 2022-01-11
On December 9, Hongri Pharmaceutical issued an announcement stating that the company had recently received a drug registration approval for rocuronium injection (2.
The imported rocuronium injection was approved for marketing in China in 2000.
-
Hengrui subcutaneously injected PD-1 into the clinic
Time of Update: 2022-01-11
From a global perspective, Pfizer has also developed a subcutaneous PD-1 monoclonal antibody sasanlimab (PF-06801591), which has entered phase 3 clinical trials, combined with BCG in the treatment of high-risk non-muscle invasive bladder cancer .
-
Researchers design a highly selective RIPK1 inhibitor with a dual mode of action of "alternative + competition"
Time of Update: 2022-01-11
More and more studies have shown that the development of highly active and selective inhibitors targeting RIPK1 can provide new approaches for the treatment of inflammatory diseases, neurological diseases, tumors, and sepsis .
-
The details of the Phase 3 study of K medicine + Lenva's failure are released!
Time of Update: 2022-01-11
Following KN189, is the new immunotherapy combination therapy expected to redefine the ceiling of the first-line treatment of NSCLC?LEAP-007: Coke combination ushered in the first failure of Phase III studyLEAP-007: Coke combination ushered in the first failure of Phase III studyIn the past, in phase Ib/II, open-label, one-arm trials (study code 111/KEYNOTE-146, NCT02501096), drug K + lenvatinib showed encouraging results in patients with metastatic NSCLC (n=21) Anti-tumor activity (ORR 33%, median PFS 5.
-
Qilu won 1 billion injections
Time of Update: 2022-01-11
A few days ago, the official website of the State Food and Drug Administration showed that Qilu Pharmaceutical's recombinant human follicle stimulating hormone for injection was approved for marketing.
-
Pfizer's oral new crown drug has a final effective rate of 89% and is effective for the Omi Keron variant
Time of Update: 2022-01-11
On December 15th, Pfizer announced its new COVID-19 oral antiviral drug candidate Paxlovid (nirmatrelvir tablets (PF-07321332); ritonavir tablets) for the treatment of non-hospitalized patients with high risk of developing severe diseases in adults with COVID-19 infection The final analysis results of the randomized, double-blind phase II/III EPIC-HR study .
-
Xinlitai Class 1 New Drug Application for Clinical Treatment of Major Depression
Time of Update: 2022-01-11
1%; the lifetime prevalence of depression in Chinese adults is 6.
With the improvement of living standards and the increase of people's health awareness, it is expected that the market for depression will continue to expand .
-
Zai Lab's Omacycline is approved and Hisun Pharmaceutical has the right to promote in China soon
Time of Update: 2022-01-11
ZL-2401 p-toluenesulfonate (Omadacycline, omacycline tosylate) is a new type of 9-aminomethylcycline drug, after chemical group modification based on the tetracycline antibiotic minocycline The resulting semi-synthetic compound has broad-spectrum antibacterial activity.
